Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for SGT-610 (Patidegib) in Gorlin Syndrome. The expected timing is based on the latest available company guidance and may change.
05/28/26:- Ph3 Gorlin topline remains on track for Q4 2026; SGT-610 patent protection extends to 2044. 08/20/26:- Ph3 Gorlin trial continues; last patient last visit is expected in September 2026. Topline results are anticipated in Late November 2026.
Verification
Confirm timing and program details against the company announcement or filing.